Selank Improves Learning and Memory Specifically in Low-Performing Rats

Selank enhanced conditioned avoidance learning and memory specifically in rats with initially low learning ability, while not significantly affecting normal learners — a deficit-correcting rather than general-enhancing effect.

Kozlovskii, I I et al.·Neuroscience and behavioral physiology·2003·Preliminary EvidenceAnimal StudyAnimal Study
RPEP-00838Animal StudyPreliminary Evidence2003RETHINKTHC RESEARCH DATABASErethinkthc.com/research

Quick Facts

Study Type
Animal Study
Evidence
Preliminary Evidence
Sample
Not reported

What This Study Found

Selank selectively enhanced conditioned avoidance learning and memory in rats with initially low learning ability while minimally affecting normal learners, demonstrating deficit-correcting rather than general cognitive enhancement.

Key Numbers

How They Did This

Animal learning study using shuttle box conditioned avoidance. Rats classified as low or normal learners. Selank administered before training. Learning acquisition and 24-hour memory retention measured.

Why This Research Matters

A cognitive enhancer that specifically helps those with deficits — without over-stimulating normal function — is the ideal nootropic profile. This selectivity suggests safety and appropriateness for clinical cognitive impairment.

The Bigger Picture

The best cognitive enhancers don't turbo-charge normal brains — they restore function where it's impaired. Selank's deficit-selective profile is therapeutically ideal for conditions like age-related cognitive decline.

What This Study Doesn't Tell Us

Rat learning model. Conditioned avoidance is a specific learning type; effects on other cognitive domains unknown.

Questions This Raises

  • ?Does Selank help human cognitive impairment similarly?
  • ?Is the deficit-selective effect related to its enkephalin-protective mechanism?
  • ?Could Selank treat age-related cognitive decline or early dementia?

Trust & Context

Key Stat:
Helps where needed Selank boosted learning specifically in underperforming rats while leaving normal performers unchanged — the ideal cognitive enhancer profile
Evidence Grade:
Preliminary animal evidence with clear performance-dependent enhancement in a validated learning paradigm.
Study Age:
Published in 2003. Selank is approved in Russia as a nootropic and anxiolytic peptide drug.
Original Title:
The optimizing action of the synthetic peptide Selank on a conditioned active avoidance reflex in rats.
Published In:
Neuroscience and behavioral physiology, 33(7), 639-43 (2003)
Database ID:
RPEP-00838

Evidence Hierarchy

Meta-Analysis / Systematic Review
Randomized Controlled Trial
Cohort / Case-Control
Cross-Sectional / Observational
Case Report / Animal StudyOne case or non-human subjects
This study

Tests effects in animals (usually mice or rats), not humans.

What do these levels mean? →

Frequently Asked Questions

Is Selank a brain booster?

It's a deficit corrector rather than a general booster. It specifically helped rats that were poor learners while barely affecting already-good learners — the ideal profile for treating cognitive impairment.

Could it help with memory problems?

In rats with learning deficits, yes. If similar effects occur in humans with age-related cognitive decline or early dementia, Selank could be a valuable treatment. It's already approved as a nootropic in Russia.

Read More on RethinkPeptides

Cite This Study

RPEP-00838·https://rethinkpeptides.com/research/RPEP-00838

APA

Kozlovskii, I I; Danchev, N D. (2003). The optimizing action of the synthetic peptide Selank on a conditioned active avoidance reflex in rats.. Neuroscience and behavioral physiology, 33(7), 639-43.

MLA

Kozlovskii, I I, et al. "The optimizing action of the synthetic peptide Selank on a conditioned active avoidance reflex in rats.." Neuroscience and behavioral physiology, 2003.

RethinkPeptides

RethinkPeptides Research Database. "The optimizing action of the synthetic peptide Selank on a c..." RPEP-00838. Retrieved from https://rethinkpeptides.com/research/kozlovskii-2003-the-optimizing-action-of

Access the Original Study

Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.

This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.